Fredun Pharmaceuticals Ltd Q3 FY2026 Concall Summary

Key Takeaways

• Growth trajectory intact, guidance comfortable: Management is "comfortable in overachieving" its guidance numbers, driven by new brands launched in the last 2–3 years gaining traction and rapid capacity expansion across 37 locations.
• New-age business is the margin story: New-age brands (Gx, pet care, nutritional, mobility, dermaceutics, cosmetics) carry 50–70% gross margins, and as their cost efficiencies kick in over the next few quarters, PAT margin will see a sudden step-up from the current 5–6% range.
• Legacy business provides a long, visible runway: The vintage portfolio is expected to grow at 12–18% YoY for the next 5–7 years, underpinned by 1,300–1,400 product registrations in the pipeline.
• Operating leverage is delayed but coming: Sequential state launches mean funds and energy keep shifting to the newest state, pushing out leverage; management expects some brands to show leverage over the next 5–6 quarters.
• What to watch next quarter: Whether the Q4 seasonal volume surge compresses margins as expected, the ramp of pet biscuits revenue, and any disclosure on the legacy vs. new-age revenue split.

Growth Engine: New-Age vs. Legacy Business

• New-age brands driving the step-up: Brands launched in the last 2–3 years across Gx, pet care, nutritional, mobility, dermaceutics and cosmetics are gaining traction and have grown at 20–25% YoY since 2020, well above the legacy rate.
• Legacy business is the steady base: Vintage products are expected to grow at 12–18% YoY for the next 5–7 years, supported by a deep pipeline of 1,300–1,400 registrations.
• Mix shift target: By 2029–2030, management wants 51% of the business to come from new-age segments. An earlier reference to "U.S. business" in the FY32 target was a mistake; the correct target is new-age business.
• Pet biscuits now contributing: The pet biscuits line started production in Q3 FY26 and is performing "phenomenally well"; revenue will begin showing from Q3 and the next quarter onwards.
• Mobility expanding scope: A physiotherapy product line under the "Fredun Mobility" umbrella launches in April, with products tailored for physiotherapists to both use and sell to clients. The mobility segment is growing at 25–30% YoY.
• Retail footprint building fast: The company is adding 30–40 retail outlets every week consistently, and plans to add another 4–5 states, which will cover almost 60% of India.

Fredun Medhora: "any number grows, the bigger it gets, you cannot sustain the same percentage growth. On a smaller number, you can sustain a percentage growth. On a larger number, it is not possible to sustain a number. It's not technically possible."

Margin Trajectory & Operating Leverage

• Current margin band is acceptable for now: Management views anything over 5–6% PAT margin as "great" at the current growth rate, because top-line growth is the priority and margins are also growing in absolute terms.
• The step-up trigger is new-age cost efficiencies: New-age brands carry intrinsically higher gross margins (50%, 60%, 70%), and once their cost efficiencies kick in, PAT margin will see a sudden increase "after a few quarters."
• Operating leverage is structurally delayed: When launching a new state like Maharashtra, operational leverage takes about 9 months. But because new states (Karnataka, Kerala) are launched sequentially, funds and energy shift to the newest state, delaying overall leverage. Over the next 5–6 quarters, some brands will begin showing leverage.
• Q4 seasonality compresses margins: The March quarter always sees higher revenue because distributors have purchase targets and year-end schemes/discounts are offered. This higher volume requires giving schemes and discounts, which compresses margins.

Fredun Medhora: "See, anything over 5%, 6% is a great margin at the rate that we are growing because our top line is growing, our margins are also growing. Margin growth, you will see a sudden increase after a few quarters once the cost efficiencies of the new-age brands start kicking in because they are intrinsically higher gross margin products, 50%, 60%, 70% gross margin products."

Balance Sheet & Working Capital

• Fundraise deployed for working capital: The fundraise money came in during Q3 and will be used for working capital needs tied to rapid expansion. No sudden need for funds is envisioned in the next 12–18 months.
• Finance cost to decline: Finance costs rose due to working capital needs, bank changes, and new machinery loans, but are expected to decline over the next 2–3 quarters.
• Inventories stable, receivables dynamic: Inventories are at the same level as the previous quarter. Trade receivables have "drastically reduced" but are dynamic due to the cyclic nature of bulk sales: on 31st March, debtor sales are slightly higher due to a 90-day credit period, while in Q1 debtor sales are lower. Averaged over 2–3 quarters, receivables are robust.
• No inventory write-off risk: Management stated there is "no question of any pertinent write-off at this point or in the conceivable future."

Mobility Segment: Slow Penetration, Strong Response

• Penetration is inherently slow: Unlike pharma, where you can place 10,000–20,000 packs, mobility requires physical placement of volumetric products (100 chairs, 300 chairs), making penetration a slower build.
• Early traction is strong: The company is selling "one of the highest numbers of wheelchairs in Maharashtra," with products present in most Mumbai locations, and expects this to continue across states as expansion proceeds.
• Physiotherapy launch in April: A new product line tailored for physiotherapists will launch under the Fredun Mobility umbrella, expanding the segment's addressable use case.

Fredun Medhora: "So penetration for any company in mobiltics is — in mobility segment is slow. But it is — for us, we have got such a good response that we are now selling I think one of the highest numbers of wheelchairs in the state. In Maharashtra, at least, we are selling — practically most of the places in Mumbai have our products, and that will continue to go across states."

Disclosure Gaps & Unanswered Questions

• Legacy vs. new-age split not disclosed: An analyst requested a revenue breakup between legacy and new-age business in quarterly earnings releases. Management did not commit, responding only: "It's a good suggestion. We'll keep that in mind."
• 9-month actuals not provided: When asked for the actual 9-month performance split of legacy vs. new-age business, management gave forward-looking growth expectations and year-end projections rather than the actual split.
• Guidance conservatism not addressed directly: When asked if guidance for the next 2–3 years seems conservative given the growth trajectory, management did not directly address the question, instead stating they are "comfortable in overachieving those."
• Trade deal question redirected: An analyst asked about the effect of the India-U.S. and India-EU trade deal on company performance. Management answered a different question, stating there will be no effect because they don't sell to the U.S. or Europe and don't intend to. When the analyst pointed out the previous transcript mentioned "U.S. business" for the FY32 target, management said it was a mistake and should be "new-age business."

Guidance & Commitments

Key Metrics